Carasent AB (publ)APXZF 82 ROC (Joel Greenblatt) % is -36.59% as of Jun. 2026. GuruFocus rates APXZF with a GF Score™ of 82/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 78.18% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Carasent AB (publ)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -36.59%.
The historical rank and industry rank for Carasent AB (publ)'s ROC (Joel Greenblatt) % or its related term are showing as below:
APXZF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -989.86 Med: 27.25 Max: 447.68
Current: 37.16
During the past 13 years, Carasent AB (publ)'s highest ROC (Joel Greenblatt) % was 447.68%. The lowest was -989.86%. And the median was 27.25%.
APXZF's ROC (Joel Greenblatt) % is ranked better than 78.18% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 12.46
vs APXZF: 37.16
Carasent AB (publ)'s 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Carasent AB (publ) (OTCPK:APXZF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Carasent AB (publ) ROC (Joel Greenblatt) % Related Terms
Carasent AB (publ) ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APXZF vs VEEV, BTSG, TEM: ROC (Joel Greenblatt) % Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s ROC (Joel Greenblatt) % falls into.
Carasent AB (publ) ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -36.59% mean?
Carasent AB (publ) (APXZF) has a ROC (Joel Greenblatt) % of -36.59% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Carasent AB (publ) and its competitors. According to the industry distribution chart, Carasent AB (publ) ranks #146 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 21.8%.
Is Carasent AB (publ)'s ROC (Joel Greenblatt) % too high?
Carasent AB (publ)'s current ROC (Joel Greenblatt) % is -36.59%. Based on the distribution chart, Carasent AB (publ) ranks #146 out of 669 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s ROC (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #146 out of 669 companies for ROC (Joel Greenblatt) %. This places Carasent AB (publ) in the top 22% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 12.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.46, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current ROC (Joel Greenblatt) % is -36.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current ROC (Joel Greenblatt) % of -36.59%. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is -36.59%. Carasent AB (publ)'s overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current ROC (Joel Greenblatt) % is -36.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
ROC (Joel Greenblatt) %: -36.59%
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
82GF Score
Get the complete analysis for APXZF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
